Copenhagen, Denmark—Substantial gains in progression-free survival (PFS) can be achieved when patients with platinum-sensitive recurrent ovarian cancer are placed on maintenance therapy with niraparib, according to results of a multinational Phase III trial.
The overall population—with or without BRCA mutations, positive or negative for homologous recombination deficiency (HRD)—“achieved a clinically significant improvement in PFS,” reported Mansoor R. Mirza, MD,